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Boron neutron capture therapy (BNCT) is a selective radiation treatment for tumors that
preferentially accumulate drugs carrying the stable boron isotope, 10B. BNCT has been
evaluated clinically as an alternative to conventional radiation therapy for the treatment of
brain tumors, and more recently, recurrent advanced head and neck cancer. Here we inves-
tigated the effect of BNCT on prostate cancer (PCa) using an in vivomouse xenograft
model that we have developed.
Materials and Methods
Mice bearing the xenotransplanted androgen-independent human PCa cell line, PC3, were
divided into four groups: Group 1: untreated controls; Group 2: Boronophenylalanine (BPA);
Group 3: neutron; Group 4: BPA-mediated BNCT. We compared xenograft growth among
these groups, and the body weight and any motility disturbance were recorded. Immunohis-
tochemical (IHC) studies of the proliferation marker, Ki-67, and TUNEL staining were per-
formed 9 weeks after treatment.
Results
The in vivo studies demonstrated that BPA-mediated BNCT significantly delayed tumor
growth in comparison with the other groups, without any severe adverse events. There was
a significant difference in the rate of freedom from gait abnormalities between the BPA-
mediated BNCT group and the other groups. The IHC studies revealed that BNCT treatment
significantly reduced the number of Ki-67-positive cells in comparison with the controls
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(mean±SD 6.9±1.5 vs 12.7±4.0, p<0.05), while there was no difference in the number of
apoptotic cells, suggesting that BPA-mediated BNCT reduced PCa progression without
affecting apoptosis at 9 weeks post-treatment.
Conclusions
This study has provided the first preclinical proof-of-principle data to indicate that BPA-
mediated BNCT reduces the in vivo growth of PCa. Although further studies will be neces-
sary, BNCT might be a novel potential treatment for PCa.
Introduction
Boron neutron capture therapy (BNCT) is a binary treatment modality for cancer that is based
on accumulation of agents containing the nonradioactive isotope boron-10 (10B), a constituent
of natural elemental boron, in cancer cells followed by irradiation with low-energy thermal
neutrons to yield high linear energy-transfer alpha particles and recoiling lithium-7 nuclei [1,
2]. Because these particles have a short path length of 5–10 μm in water, the cytotoxic effects
are confined within boron-10-containing cells, if 10B atoms are selectively accumulated in
tumor cells. Thus, in order for BNCT to succeed, it requires selective delivery of large amounts
of 10B to tumor cells.
10B-containing compounds can be accumulated selectively into tumor cells by several mech-
anisms. Two of the most common 10B-carriers used in clinical BNCT trials, designed for the
treatment of malignant gliomas, melanomas, inoperable head and neck tumors, and oral can-
cer, are L-para-boronophenylalanine-10B (BPA, C9H1210BNO4) and sodium mercaptounde-
cahydrododecaborate-10B (BSH, Na210B12H11SH)[1]. BPA was originally evaluated as a
boron delivery agent for melanoma, and BNCT of BPA-loaded tumors resulted in high levels
of tumor control [3]. BPA is selectively and preferentially accumulated into tumor cells as a
result of augmented amino acid metabolism by active transport across the cancer cell mem-
brane in comparison with normal cells [4]. BPA has been utilized in experimental studies of
brain tumor therapy [5, 6] following reports indicating that it was preferentially accumulated
in rat gliosarcoma, human glioma xenografts, and murine mammary adenocarcinoma [7].
BSH relies on the blood-brain barrier to achieve selective accumulation in tumor cells relative
to normal brain [8]. BSH does not cross the intact blood-brain barrier in the normal brain but
is delivered to tumors because the tumor vasculature does not form the tight junctions associ-
ated with the blood-brain barrier. Since the boron concentrations achieved with BSH in the
blood can be as high as in the tumor, damage to the vascular endothelial cells in the brain
would be the primary determinant of radiation damage to the central nervous system [9].
BNCT has been evaluated clinically as an alternative to conventional radiation therapy for
malignant brain tumors (gliomas), and more recently, recurrent locally advanced head and
neck cancer [10]. However, there have been few reports on the use of BNCT for treatment of
prostate cancer (PCa). In the present in vivo study, therefore, we assessed whether BPA-medi-
ated BNCT would affect the growth of the xenografted androgen-independent PCa cell line,
PC3. We found that BPA-mediated BNCT reduced the growth of PC3 xenografts without any
severe adverse events.
This study provides the first preclinical proof-of-principle data to indicate that BPA-medi-
ated BNCT reduces the growth of PCa xenografts in vivo, suggesting that this might be a prom-
ising new therapeutic approach for patients with PCa.
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Materials and Methods
Cell lines
PC3 cells were purchased from the American Type Culture Collection (ATCC, Rockville, MD,
USA). The cells were maintained in RPMI1640 supplemented with 10% fetal bovine serum
(FBS) and 1% penicillin/streptomycin (Life Technologies, Burlington, Ontario, Canada) at
37°C in a 5% CO2 atmosphere.
Boron compounds
BPA was kindly provided by Dr. Mitsunori Kirihata (Research Center for Boron Neutron Cap-
ture Therapy, Research Organization for the 21st Century, Osaka Prefecture University, Sakai,
Japan), and converted to a fructose complex. An aqueous solution of the BPA complex was pre-
pared at a concentration of 250 mg/ml (21.28 mg 10B/ml). In order to evaluate 10B concentra-
tions in mice, BPA was injected intraperitoneally at a dose of 250 mg/kg in accordance with
previous studies [11, 12].
Determination of boron concentration by ICP-AES
This study was carried out in strict accordance with the recommendations in the Guide for the
Care and Use of Laboratory Animals of the National Institutes of Health (S1 ARRIVE Check-
list). The protocol was approved by the Osaka Medical College Animal Care and Use Commit-
tee (Permit Number: 26075). All surgeries were performed under anesthesia by 2% isoflurane
inhalation, and all efforts were made to minimize suffering. Quantitative determination of
boron was carried out by the inductively coupled plasma atomic emission spectrometric
(ICP-AES) method. PC3 cells (1x106) with 50 μl of Matrigel (Becton Dickinson Labware,
Franklin Lakes, NJ) and 50 μl of serum-free RPMI1640 were injected subcutaneously into the
back of the leg of 6~8-week-old male athymic nude mice with a 27-gauge needle under anes-
thesia by 2% isoflurane inhalation. At week 2 after PC3 cell injection, when PC3 xenografts
were palpable, BPA complex at a concentration of 250 mg/ml (21.28 mg 10B/ml) was injected
intraperitoneally into tumor-bearing mice. Samples of heart, blood, brain, liver, kidney, lung,
and tumor were collected at 2 and 4 h after injection, digested with nitric acid solution, stored
in distilled water at room temperature overnight, and then subjected to the boron concentra-
tion assay using an ICP-AES instrument (SPS 3100;SSI; Nanotechnology, Tokyo, Japan). The
numbers of mice in each group were 3.
BNCT for PC3 xenografts
PC3 cells (1x106) with 50 μl of Matrigel and 50 μl of serum-free RPMI1640 were injected sub-
cutaneously into the back of the leg of 6~8-week-old male athymic nude mice with a 27-gauge
needle under anesthesia by 2% isoflurane inhalation. The day of injection of PC3 cells was
taken as the starting point and defined as day 0. At week 2 after PC3 cell injection, when PC3
xenografts were palpable, the mice were divided into four groups: Group 1: untreated control,
Group 2: BPA, Group 3: neutron, and Group 4: BPA-mediated BNCT. The numbers of mice in
each group were 6. In Groups 3 and 4, the tumors in the leg were subjected to thermal neutron
beam irradiation at the heavy water facility of Kyoto University Research Reactor for 60 min at
a power of 1 MW. Each mouse was held within a specially designed acrylic cage during irradia-
tion, and a LiF plate (50 mm thick) was used to shield the body from thermal neutrons while
the tumor-inoculated leg was exposed. In Group 4, BPA was administered intraperitoneally 2
hours before irradiation at a dose of 250 mg/kg. Tumor volume measurements were performed
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once a week and calculated using the formula: length x width x depth x 0.5236 [13]. At 9 weeks,
the mice were sacrificed and the tumors were prepared for histological examination.
Histological examination
For immunohistochemistry, tissues were embedded in OCT compound (Miles Scientific,
Elkhardt, IN) and snap-frozen in liquid nitrogen. Frozen sections 6 μm thick were mounted on
silane-coated glass slides, and air-dried for 1 h. Cell apoptosis was confirmed by detection of
fragmented DNA, using a DeadEnd Colorimetric TUNEL System (Promega, Madison, WI) in
accordance with the manufacturer’s instructions. As markers of cell proliferation, sections
were stained with anti-Human Ki-67 eFluor 570 (eBioscience, Frankfurt, Germany, 1:200) and
anti-SMa-actin (Sigma-Aldrich Japan K.K., Tokyo, Japan, 1:500). Nuclear counter-staining was
performed by incubation with 4',6-diamidino-2-phenylindole (DAPI) solution (Sigma-Aldrich,
1 μg/ml in PBS) for 10 min at room temperature. Double-positive cells were counted and aver-
aged for quantitative analysis.
Statistical analysis
All values obtained in immunohistochemical (IHC) studies are presented as mean ± SD, and
those for in vivo body weight, tumor volume, and measurement of 10B concentrations are pre-
sented as mean ± SEM. Statistical comparisons between two groups were performed by
unpaired Student’s t test. The periods during which mice remained free of any gait abnormali-
ties were converted to Kaplan-Meier plots, and the significance of differences between them at
p<0.05 was calculated using the generalized log-rank test.
Results
Timing of peak 10B concentration after intraperitoneal injection of BPA
10B concentrations were first measured by the boron concentration assay using an ICP-AES
instrument in the heart, blood, brain, liver, kidney, lungs, and tumor of PC3 tumor-bearing
mice in order to assess the optimum period for neutron capture after intraperitoneal injection
of BPA at 250 mg/kg with a 27-gauge needle under anesthesia by 2% isoflurane inhalation. In
every organ, mice showed high peak 10B concentrations at 2 hours, as compared with those at 4
hours. 10B concentration in tumor both at 2 and 4 hours were high as compared with 10B con-
centration in other organs, especially at 2 hours (10B concentrations in tumor at 2 and 4 hours
were 6.77±2.09 and 1.89±0.91 μg/g, respectively) (Fig 1). Therefore we concluded that the best
time point for neutron capture therapy was 2 hours after injection.
Assessment of effect of BPA-mediated BNCT on body weight of mice
during the treatment period
In order to assess whether BPA-mediated BNCT influenced the growth and body weight of
mice, the animals were monitored once a week from 0 week to 9 weeks. The day of injection of
PC3 cells was taken as the starting point and defined as day 0. At week 2 after PC3 cell injec-
tion, when PC3 xenografts were palpable, the mice were divided into four groups: Group 1:
untreated control, Group 2: BPA, Group 3: neutron, and Group 4: BPA-mediated BNCT. The
mean body weights of the mice in the four groups are shown in Fig 2. No significant effect on
animal body weight was observed during the treatment period. These results indicated that
none of the treatments—BPA, neutron irradiation or BPA-mediated BNCT—produced severe
side effects in this in vivo mouse xenograft model.
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Effect of BPA-mediated BNCT treatment on growth of PC3 xenografts
The sizes of the tumors in the four groups of model mice were monitored for up to 9 weeks.
Untreated control mice (Group 1) and BPA-treated mice (Group 2) showed rapid xenograft
growth, and the average tumor volume at 9 weeks after the start of the experiment was 1611
mm3 and 1589 mm3, respectively. Mice subjected to neutron irradiation (Group 3) showed
slightly slow xenograft progression, and the average tumor volume reached 1151 mm3 at 9
weeks. However, when the xenografts were subjected to BPA-mediated BNCT (Group 4),
tumor progression was markedly reduced from 2 weeks after BNCT, and average tumor vol-
ume at 9 weeks was 202 mm3. The differences in tumor volume between Group 4 and Groups
1, 2 and 3 at 8 and 9 weeks after the start of the experiment were significant (Fig 3A) (p<0.05).
Macroscopic observation revealed that mice in Groups 1, 2 and 3 had clearly enlarged palpable
Fig 1. Time course changes of 10B concentration in 6 tissues. 10B concentration in the heart, blood, brain,
liver, kidney, lungs, and tumor of PC3 tumor-bearing mice were measured by ICP-AES instrument at 2 and 4
hour after intraperitoneal injection of 250 mg/kg BPA.
doi:10.1371/journal.pone.0136981.g001
Fig 2. Themean body weight of mice in four groups.Mean body weight of mice (Group 1: untreated
control, Group 2: BPA, Group 3: neutron, Group 4: BPA-mediated BNCT) from 0 to 9 week were shown. Each
point represents the mean body weight ± SEM.
doi:10.1371/journal.pone.0136981.g002
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tumors, whereas the tumors in Group 4 mice were almost undetectable (Fig 3B). These xeno-
graft studies demonstrated that BPA-mediated BNCT significantly delayed PCa growth with-
out any severe adverse events.
Effect of BPA-mediated BNCT in terms of gait abnormalities
In order to examine how much the degree to which PC3 tumor xenografts influenced the gait
of freely moving mice, we next assessed the motility of mice in all groups. Mice that had been
treated with BPA (Group 2) and neutron irradiation (Group 3) developed gait abnormalities
by day 56 and day 63, respectively, whereas about 66.7% of the untreated control mice (Group
1) also showed gait anomalies by day 56. However, none of the mice subjected to BPA-medi-
ated BNCT (Group 4) developed motility disturbance during the treatment period (Fig 4).
Consistent with the result that the differences in tumor volume between Group 4 and Groups
1, 2 and 3 at late stage during the treatment were significant, the rates of freedom from gait
abnormalities differed significantly between Group 4 and Groups 1, 2 and 3 (p<0.05). These
results demonstrated that PC3 xenograft growth was markedly suppressed by BPA-mediated
BNCT.
Immunohistochemical (IHC) studies of xenograft tissue
At 9 weeks post-treatment, tissue samples from untreated control mice (Group 1) and mice
subjected to BPA-mediated BNCT (Group 4) were first examined histologically using standard
hematoxylin and eosin (H&E) staining after formalin fixation. In both groups, vacuolated
tumor cells with multiple nuclear fragmentations were observed, although the histological find-
ings did not differ significantly between them (data not shown). Next, in order to assess how
Fig 3. (A) Tumor volume of mice in four groups 2 to 9 weeks after PC3 injection.Mean tumor volume of
mice (Group 1: untreated control, Group 2: BPA, Group 3: neutron, Group 4: BPA-mediated BNCT) from 2 to
9 week were shown. Each point represents the mean tumor volume ± SEM. *P<0.05 differs from Group 1, 2,
and 3 by Student’s t test. (B) Macroscopic findings in four groups at 9 weeks.White arrows indicate sites
of tumor.
doi:10.1371/journal.pone.0136981.g003
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BPA-mediated BNCT affected PC3 xenograft growth, immunohistochemistry for the prolifera-
tion marker, Ki-67, and TUNEL staining were performed on PC3 xenograft specimens from
Groups 1 and 4. Apoptosis was observed in both groups, without any obvious differences
between them, and quantification of apoptotic cells also indicated no significant inter-group
difference (Fig 5). However, double-positive staining for Ki-67 was observed significantly more
frequently in Group 1 than in Group 4 (mean±SD 12.7±4.0 vs 6.9±1.5, respectively, p<0.05)
(Fig 6). These IHC studies suggested that BPA-mediated BNCT slowed PCa progression with-
out affecting apoptosis at 9 weeks post-treatment.
Discussion
PCa is now a major and escalating international health problem among men, and is one of the
most common malignant solid tumors in Western countries [14]. Androgen deprivation ther-
apy (ADT) is the gold standard for recurrent or advanced PCa [15]. Although most PCa
patients are initially dependent on androgens for tumor growth, and apparently respond well
to ADT, most patients invariably develop treatment resistance at some stage, developing a cas-
tration-resistant (CR) status with an eventual fatal outcome even after potentially curative
treatment. Therefore, there is an urgent need for a novel therapeutic strategy that can overcome
the emergence of CR PCa.
BNCT is a selective tumor cell radiation treatment for tumor cells that is based on preferen-
tial intracellular accumulation of drugs carrying the stable boron isotope, 10B. The first BNCT
trials were conducted on ten patients with terminal glioblastoma multiforme brain tumors
between 1951 and 1953 [16]. In this trial, water-soluble 10B-enriched sodium borate (borax,
Na2B4O7), which was considered relatively non-toxic at therapeutic concentrations of up to
200 mg per kg body weight, was used as the initial BNCT drug. However, all ten patients died
due to tumor recurrence without prolongation of their survival times. Further clinical trials
Fig 4. Percentages of animals without gait abnormalities in the four groups.Gait abnormalities of mice
(Group 1: untreated control, Group 2: BPA, Group 3: neutron, Group 4: BPA-mediated BNCT) were
observed. The percentages of animals without gait abnormalities differed significantly between Group 4 and
Groups 1, 2 and 3 (p<0.05).
doi:10.1371/journal.pone.0136981.g004
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Fig 5. TUNEL staining on PC3 xenograft specimens. Xenograft tissues of mice (Group 1: untreated
control and Group 4: BPA-mediated BNCT) were stained with TUNEL and the number of apoptotic cells was
quantified. White arrows indicate TUNEL+ cells.
doi:10.1371/journal.pone.0136981.g005
Fig 6. Ki67 staining on PC3 xenograft specimens. Xenograft tissues of mice (Group 1: untreated control
and Group 4: BPA-mediated BNCT) were stained with Ki67, SMa-actin, and DAPI (A:DAPI B:Ki67 C:SMa-
actin D:Mixed). Quantification of Ki67-positive cells was shown.
doi:10.1371/journal.pone.0136981.g006
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were then conducted with several 10B-containing compounds, and BNCT was introduced to
Japan in 1968 by the neurosurgeon Hiroshi Hatanaka [17], who used sodium borocaptate
(BSH) and a low-energy thermal neutron beam with low tissue-penetrating properties. In more
recent clinical trials in Japan, our co-authors Miyatake and Kawabata have initiated several
protocols employing a combination of BPA (500 mg/kg) and BSH (100 mg/kg), infused i.v.
over 2 hours, followed by neutron irradiation at Kyoto University Research Reactor Institute
(KURRI) [18, 19]. Miyatake et al. demonstrated that BNCT conferred a survival benefit for
patients with recurrent malignant glioma, especially for those who were at high risk [19].
Kawabata et al. reported that BNCT utilizing sodium borocaptate and boronophenylalanine
simultaneously in combination with X-irradiation enhanced the survival of patients with newly
diagnosed glioblastoma, in comparison with BNCT alone [18]. Another study by that group
demonstrated that a combination of transferrin-conjugated polyethylene glycol (TF-PEG)
liposomes encapsulating sodium borocaptate and Iomeprol with intratumoral convection-
enhanced delivery (CED) enabled not only precise and potent targeting of boron to the tumor
tissue, but also tracing of boron administered intratumorally using real-time computed tomog-
raphy [20].
For extracranial tumors, BNCT was reported to be a new and promising treatment
approach in 26 patients (19 squamous cell carcinomas (SCC), 4 salivary gland carcinomas and
3 sarcomas) with recurrent and far advanced head and neck malignancies [21]. Recently, one
of our co-authors, Suzuki, and colleagues reviewed the outcomes of BNCT in 62 patients with
either locally recurrent or newly diagnosed unresectable head or neck cancers [22]. Using
either BPA alone, or BPA combined with other boron compounds, the dose constraint was
delivery of<10–12 Gy-eq to the skin or oral mucosa, and this was shown to be a feasible dose-
estimation method for BNCT in this setting.
Moreover, in order to identify potential tumors that may be amenable to BNCT and to
improve treatment plans prior to BNCT, the accumulation of BPA to the tumor and surround-
ing normal tissue is imaged and quantified by an 18F-BPA PET study before BNCT [23, 24].
Thermal neutron fluence is measured by radioactivation of gold wires (0.25 mm in diameter
and 1.0 cm long) placed on the skin surface of the lesion, and the dose-volume histogram
(DVH) parameters are evaluated by a Simulation Environment for Radiotherapy Applications
(SERA) system and the Japan Atomic Energy Research Institute’s Computational Dosimetry
System, which are currently available BNCT treatment-planning systems [25].
On the other hand, there have been few reports of clinical trials of BNCT or basic research
in the context of PCa. Schinazi et al. initially indicated that among the carboranyl nucleotides
beta-D-5-o-carboranyl-2'-deoxyuridine (D-CDU), 1-(beta-L-arabinosyl)-5-o-carboranyluracil
(D-ribo-CU) and the nucleotide base 5-o-carboranyluracil (CU), CU was the most suitable
compound for BNCT in vivo using the androgen-dependent PCa cell line, LNCaP [26]. In
another study, enhanced cell killing was observed when the BPA-loaded PCa cell line, DU145,
was irradiated using a modified enhanced thermal neutron beam (METNB) assembly devel-
oped at Fermi National Accelerator Laboratory (Fermilab) [27]. Recently, Gifford et al. demon-
strated that liposome-based delivery of a boron-containing cholesteryl ester compound (BCH)
was capable of introducing sufficient boron into PC3 cells for BNCT, and that high-linear
energy transfer (High-LET) particles and 7Li nuclei generated by 10B thermal neutron capture
significantly decreased the colony formation ability of targeted PC3 cells in vitro [28].
In the present study, we carried out in vivo experiments using BPA-mediated BNCT in the
androgen-independent PCa cell line, PC3. Our xenograft studies demonstrated that BPA-
mediated BNCT significantly delayed PCa growth with no severe adverse events as compared
with other groups (untreated control, BPA only, and neutron irradiation only), and IHC stud-
ies suggested that BPA-mediated BNCT reduced PCa progression without affecting apoptosis.
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However, before clinical trials of BNCT for PCa patients can begin, some problems remain to
be resolved. One of them is neutron capture, as neutrons can only reach organs close to the
body surface, and their effect decreases with increasing depth. For this reason, if the prostate is
neutron-irradiated from a normal direction, BNCT would probably not be effective even if
BPA is successfully delivered to PCa. Therefore, we consider that if neutrons could be delivered
transperineally from a normal direction, then the distance between the prostate and the body
surface would be considerably reduced.
With regard the toxicity after BNCT, we note that we have previously treated 62 patients
with head-neck cancer, and observed hyperamylasemia (38.6%), fatigue (6.5%), mucositis/sto-
matitis (9.7%) and pain (9.7%), as major acute Grade 3 or 4 toxicities, while all of which were
manageable [22]. BNCT for PCa patients has not been performed clinically, however, the
above-mentioned side effects would be observed if neutrons could be delivered transperineally.
In conclusion, our present in vivo study has provided the first preclinical proof-of-principle
data to indicate that BPA-mediated BNCT can suppress the growth of androgen-independent
PC3 xenografts. In order for BNCT to be applied to PCa patients in clinical trials, however,
some problems such as the direction of neutron irradiation need to be resolved. However,
BNCT appears to hold promise as a novel treatment for PCa.
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